Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis by Len Claudio A et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Research
Homocysteine and lipid profile in children with Juvenile Idiopathic 
Arthritis
Marcela Gonçalves1, Vânia D'Almeida1, Elvira M Guerra-Shinohara2, 
Luciano C Galdieri1, Claudio A Len1 and Maria Odete E Hilário*1
Address: 1Department of Pediatrics, Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil and 2Department of Clinical Chemistry and 
Toxicology, Faculty of Pharmaceutical Science, Universidade de São Paulo (USP), São Paulo, Brazil
Email: Marcela Gonçalves - marcela.goncalves@terra.com.br; Vânia D'Almeida - alergia.reumato@terra.com.br; Elvira M Guerra-
Shinohara - alergia.reumato@terra.com.br; Luciano C Galdieri - alergia.reumato@terra.com.br; Claudio A Len - len.cl@terra.com.br; 
Maria Odete E Hilário* - odetehilario@terra.com.br
* Corresponding author    
Abstract
Background: An increased concentration of plasma homocysteine (Hcy) has toxic effects on vascular
endothelium. This seems to be a risk factor of cardiovascular disease, premature stroke and venous
thrombosis. The risk is higher in coincidence with other factors like chronic diseases and familiar
hypercholesterolemia. The aim of our study was to evaluate plasma Hcy concentration in patients with
juvenile idiopathic arthritis (JIA) and its correlation with methotrexate (MTX) therapy, serum folate and
B12 vitamin, and hyperlipidemia.
Methods: Fifty-one patients (37 females; mean age 11.3 years, range 2.3–17 years) with JIA and 52 healthy
controls (42 females; mean age 12.5 years; range 3–18 years) were included in the study. Thirty-two
patients were using weekly MTX (mean doses: 0.1–1 mg/kg). For statistical analysis both JIA and control
groups were distributed in three subgroups according to age (3 – 7, 8 – 12 and 13 – 18 years). The
laboratory investigation included measurement of erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), plasma Hcy, serum folate, vitamin B12, triglycerides, total cholesterol, high-density
lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL). For data
analysis, we considered raised Hcy values ≥ 12.56 µmol/L, which corresponds to the 90th percentile
observed in the control group.
Results: The mean plasma Hcy concentration was 9.3 ± 3.16 µmol/L in JIA patients and 8.9 ± 2.42 µmol/
L in healthy controls (p = 0.615). Higher concentration of Hcy was observed in the subgroup of 13 – 18
years (patients and controls, p < 0.001). We did not find correlation between MTX use and plasma Hcy
concentration. With regard to vitamin B12 concentration, we detected normal values in both patients and
controls while serum folate concentration was higher in patients (p < 0.001). With regard to the
lipidogram, lower concentration of HDL was found in patients (p = 0.007) and higher levels of VLDL (p =
0.014) and triglycerides (p = 0.001) were observed in controls. We did not observe correlation among
plasma Hcy concentration, clinical findings, ESR and CRP.
Conclusion: JIA patients do not present significant increased concentration of Hcy despite the use of
MTX, probably due to the folate supplementation. The mild abnormalities in the lipidogram may reflect a
current concern with diet and health.
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Background
Homocysteine (Hcy) is a sulphydryl amino acid derived
from the essential amino acid methionine during its con-
version to cysteine [1]. Its main metabolic pathways
require folic acid and vitamins B6 and B12. Its concentra-
tions depend on age, gender and ethnic background [2].
Hcy has many functions: threshold of the auto-oxidation
of low-density lipoprotein (LDL) [3], promote vascular
smooth-muscle cell proliferation, platelet activation and
endothelium dysfunction [4].
Both in children and in adults increased concentration of
plasma Hcy has direct and indirect toxic effects on the vas-
cular endothelium and seems to be one more risk factor
of cardiovascular disease, premature stroke and venous
thrombosis [5], especially when associated with other risk
factors like familiar hypercholesterolemia.
Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory disease in which clinical manifestations may persist
for decades in some patients despite adequate treatment
[6]. There are two studies about the level of Hcy in chil-
dren with JIA and the results have been conflicting [7,8].
Huemer [7] et al evaluated Hcy levels in 17 patients with
JIA using methotrexate (MTX) with or without folic acid
supplementation and in controls matched for age and
gender. The average Hcy concentration in 17 patients was
significantly higher than in the controls. However, a rela-
tion between the Hcy concentration and treatment with
MTX or folic acid was not found. The same authors [8] fur-
ther evaluated 35 JIA patients and healthy controls with
the purpose of determining the Hcy concentration and
genetic polymorphism capable of increasing the Hcy con-
centration in this population. In this study the Hcy con-
centration was lower in the patients than in the controls.
The paucity of studies about this subject and the conflict-
ing results published to the present date stimulated us to
evaluate this metabolite in children and adolescents with
JIA.
Methods
Subjects
A cross-sectional study involving 51 children and adoles-
cents with JIA (37 girls, current average-age 11.3 years)
selected consecutively from our outpatient Pediatric
Rheumatology Unit was performed. All of them were
diagnosed according to the International League of Asso-
ciations for Rheumatology (ILAR) [9]. Fifty-two "healthy"
children and adolescents (42 girls, current mean-age 12.5
years) selected from a public school in the same area were
included as controls. None of the controls presented a
family history of autoimmune disease. Both patients and
controls denied cigarette or alcohol use.
Disease activity
All patients were clinically evaluated by a board certified
pediatric rheumatologist. We defined active JIA when the
patient presented one or more joints with arthritis at the
time of the study. We also measured the ESR and CRP of
all patients.
Laboratory study
Patients and controls samples were identified by an
unknown code by the laboratory staff. Thirty milliliters of
blood were collected from fasting participants and centri-
fuged at 3000 rpm for 5 minutes. The plasma was sepa-
rated in aliquots and immediately frozen and stored at -
80°C. The time between the beginning and the end of this
process did not exceed one hour.
One portion of each blood sample was used to determine
the total Hcy concentration, the concentration of vitamin
B12 and serum folate. The leftover blood sample was used
to determine the total cholesterol level (TC) and its frac-
tions, and triglycerides (TG).
Total plasma Hcy concentration was measured according
the method proposed by Pfeiffer et al, which uses the
High Performance Liquid Chromatography (HPLC) with
fluorimetric detection and isocratic elution [10].
Increased Hcy concentration was defined as plasma Hcy
concentration equal to or higher than 12.56 µmol/L (90th
percentile of the control group).
Vitamin B12 concentration was performed by an enzyme
immunoassay method with micro particles (Imx B12 ® of
Abbot Laboratories). Serum folate concentrations were
measured by ionic capture (Imx Folate ® of Abbot Labora-
tories).
TC, high-density lipoprotein (HDL), LDL, very low-den-
sity lipoprotein (VLDL), serum creatinine as well as TG
were measured by the enzymatic colorimetric method.
Statistical Analysis
For statistical analysis both JIA and control groups were
distributed into 3 subgroups according to age (3 – 7 year-
old, 8 – 12 year-old and 13 – 18 year old).
To establish a reference value (cutting point) in order to
make comparisons between the groups of patients and
controls, a receiver operating characteristics (ROC) curve
analysis was conducted and after that, the categorization
by the 90th percentile of the control group.
Some variables like Hcy concentration, TC and its frac-
tions, TG, vitamin B12, serum folate concentrations and
serum creatinine were transformed into logarithm (Log10)Pediatric Rheumatology 2007, 5:2 http://www.ped-rheum.com/content/5/1/2
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due to the variability and asymmetry of values, in order to
obtain a normal probability distribution.
For the comparison of categorical variables of Hcy, the
chi-square test was used, and when necessary (expected
values lower than five), the Fisher's exact test was used.
The Student's t-test was used for the comparison of con-
tinuous variables. The relation between Hcy concentra-
tion and other continuous variables was analyzed by
Spearman's correlation coefficient.
To evaluate the relation between high and normal Hcy
concentration groups of normal and high values and the
other variables in each group, the logistic regression anal-
ysis with logic model was used to estimate odds ratio.
Univariate and multivariate analysis were conducted
using the stepwise variables selection criteria.
The level of significance adopted for the statistical tests
was 5%, that is, p < 0.05.
The study protocol was approved by the Ethics Committee
of the Universidade Federal de São Paulo. A consent form
was obtained for each patient and control either from a
parent, guardian or responsible adult before inclusion in
the study.
Results
The demographic and clinical characteristics of the
patients are presented in table 1. We observed a predomi-
nance of the female gender (72.6%) and oligoarticular
onset type (43.1%); 52.9% of the patients had active dis-
ease and 62.7% were taking MTX.
Average serum Hcy concentration was 9.3 ± 3.16 µmol/L
in JIA patients and 8.9 ± 2.42 µmol/L in healthy controls
(p = 0.615) (Table 2). Only 5 patients (9.8%) and 5 con-
trols (9.6%) presented high levels of Hcy (Figure 1). Con-
sidering the age groups, higher average plasma Hcy
concentration was observed in patients from 13 to 18
years of age (p < 0.001) (Table 3). No difference in the
Hcy concentration was observed between gender in
patients (p = 0.293) and controls (p = 0.794).
With regard to the analysis of the Hcy concentration, we
did not observe significant differences in relation to the
onset and course types of disease and MTX. No correlation
among Hcy plasma concentration or clinical and labora-
tory parameters in JIA patients was observed.
Vitamin B12 concentration was normal in patients and
controls while serum folate concentration was higher in
patients than in controls (11.25 ng/ml ± 4.72 and 6.66
ng/ml ± 2.27 p < 0.001) (Table 2). None of the patients
presented folate levels below the value considered nor-
mal.
Regarding the lipidogram, 7 patients presented total cho-
lesterol levels varying between the limitrophe and the
increased value (p = 0.398) (Table 2). A lower concentra-
tion of HDL was found more frequently in patients than
in controls (39.00 mg/dL and 43.58 mg/dL, p = 0.007).
Higher levels of VLDL (p = 0.014) and triglycerides (p =
0.001) were observed in controls (71.24 × 93.98 mg/dL)
(p = 0.001) (Table 2).
Discussion
JIA is a chronic inflammatory disease that affects young
children and adolescents. In this disease the mortality is
low, and many patients have a good quality of life in their
adult years. Studies with normal adults and rheumatoid
arthritis patients have shown a correlation between
plasma Hcy concentration and the presence of cardiovas-
cular and thromboembolic events [11,12]. This data is of
great importance given that the abnormalities in the Hcy
concentration can be changed during childhood and ado-
lescence, leading to a higher survival rate and to a better
quality of life. However, in childhood the relationship
among Hcy, vitamin B12 and folate has not been well
determined yet.
In this study we observed an elevated concentration of
plasma Hcy in some children with JIA and also in some
controls. We found a significant difference between two
groups of patients: 3 to 7 year-old and 13 to 18 year-old
(p < 0.001). Some studies relate age to an increase in Hcy
levels, especially in children who are over 10 [13-15]. In
the control group we observed a higher value in children
between 8 and 12 years of age (p = 0.107). However, we
did not observe significant differences between the
patients and the controls (average = 9.3 µmol/L × 8.9
µmol/L, respectively, p = 0.615).
In the present study we observed a progressive increase in
the average concentration of Hcy in patients with JIA and
controls related to age.
There are few articles about the subject. Huemer et al [7]
studied 17 patients with JIA, all of them using MTX, and
17 controls matched for gender and age. These authors
showed patients presented a higher Hcy concentration
when compared with the controls (p < 0.04). In another
study 35 children with JIA and 62 controls were evaluated.
The authors did not find significant increase of the Hcy
concentration in both groups [8].
Hcy serum concentration can be a result of several factors
including: genetic aspects [13,16], age [14], lifestyle [17],Pediatric Rheumatology 2007, 5:2 http://www.ped-rheum.com/content/5/1/2
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biochemical alterations as folate deficiency [18], certain
medications [19] and some diseases [20].
One of the main determinant factors of the Hcy concen-
tration is folate [18], due to its participation in the
remethylation process. Studies with healthy children
showed a correlation between low serum folate and
cobalamin and elevated Hcy [2,14]. In our subjects,
abnormalities in concentration of vitamin B12 were not
observed; we detected an increase in folate concentration
in patients when compared to controls (p < 0.001), prob-
ably related to folic acid supplementation.
It is known that MTX takes part in Hcy metabolism
increasing its plasmatic concentration [21]. Van Ede et al
evaluated 113 patients with rheumatoid arthritis using
MTX and concluded that a small dosage of this drug may
increase Hcy concentration [22]. According to our results,
4/5 patients with elevated Hcy concentration were taking
MTX.
Corticosteroids, diuretics and immunosuppressive drugs
like azathioprine and cyclosporine may interfere with Hcy
concentration [23]. In our study, a patient with polyartic-
ular JIA used azathioprine and 3 patients with polyarticu-
Table 2: Hcy, vitamin B12, folate, cholesterol fractions and triglycerides concentrations in patients (n = 51) and controls (n = 52).
Hcy Vitamin B12 Folate VLDL HDL LDL TG
Patients
mean (SD) 9.27 (3.16) 552 (315.5) 11.25 (4.72) 15.43 (5.19) 39.0 (7.67) 94.75 (20.41) 71.24 (23.33)
Controls
mean(SD) 8.92 (2.42) 484.5 (246.6) 6.66 (2.27) 20.12 (11.01) 43.58 (9.21) 89.81 (19.15) 93.98 (41.17)
p value 0.615 0.341 < 0.001 0.014 0.007 0.208 0.001
Hcy = homocysteine (µmol/L); VLDL = very low density lipoprotein (mg/dL); HDL = high density lipoprotein (mg/dL); LDL = low density 
lipoprotein (mg/dL); TG = triglycerides (mg/dL)
Table 1: Demographic and clinical characteristics of patients with juvenile idiopathic arthritis (N = 51) and controls (N = 52).
Patients Controls
Epidemiological 
Characteristics
n( % )n( % )
Gender
Female 37 (72.6) 42 (80.1)
Male 14 (27.4) 10 (19.9)
Origin
Caucasian 38 (74.5) 27 (51.9)
Non Caucasian 13 (25,5) 25 (48.1)
Age at disease onset 
(years)
Range 1–12 -
Mean ± SD 5.6 ± 3.2 -
Median 5.8 -
Current age (years)
Medium ± DP 11.3 ± 4.2 12.5 ± 3.5
Median 12.3 13
Onset type JIA
Oligoarticular 22 (43.1%) -
Polyarticular 17 (33.3%) -
Systemic 12 (23.6%) -
Course type
Oligoarticular 29 (56.9%) -
Polyarticular 22 (43.1%) -
Active disease treatment 27 (52.9%)
Methotrexate 32 (62.7%)
NSAIDs 26 (51%)
Chloroquine 10 (13.9%)
Folic acid 32 (62.7%)
Systemic steroids 4 (7.8%)
JIA: juvenile idiopathic arthritis, NSAIDs: nonsteroidal anti-inflammatory drugsPediatric Rheumatology 2007, 5:2 http://www.ped-rheum.com/content/5/1/2
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lar course used cyclosporine. Only one of these showed an
elevated Hcy concentration.
Chiang et al [24] reported a positive correlation between
ESR and Hcy concentration after the methionine load test.
Friso et al [25] did not obtain this positive correlation
between Hcy concentration and the CRP in 891 subjects.
In our study we did not find significant data which could
correlate Hcy concentration with ESR and CRP levels.
Dyslipidemia may be found in some rheumatic diseases
especially related to disease activity and corticosteroid use
[26]. Its relation with the mechanism of arteriosclerosis
and cardiovascular diseases is studied worldwide [27].
Dyslipidemia was also reported in children with JIA and
systemic lupus erythematosus (SLE). In a study with 37
children with chronic arthritis and 9 with active disease,
the levels of TC and fractions, TG and apoliprotein were
measured. This study showed an insignificant diminution
of LDL in the patients with active disease when compared
to either patients without active disease or to controls.
This study also showed low concentrations of apolipro-
tein A1 in patients with disease activity when compared to
patients out of activity and controls [28]. In 1988, Ilowite
Table 3: Average serum homocysteine concentration of patients with juvenile idiopathic arthritis (n = 51) and controls (n = 52), 
according to age group.
Average serum Hcy (µmol/L) SD
Patients (n = 51)
3 – 7 year-old (n = 13) 7.29 * 1.45
8 – 12 year-old (n = 16) 8.62 1.87
13 – 18 year-old (n = 22) 10.93 * 3.80
Controls (n = 52)
3 – 7 year-old (n = 6) 7.42 3.98
8 – 12 year-old (n = 19) 9.51 4.18
13 – 18 year-old (n = 27) 8.92 5.62
Hcy = homocysteine, SD = standard deviation
* Patient subgroups: 3 – 7 year-old vs. 13 – 18 year-old (p < 0.001)
Homocysteine concentration in patients (N = 51) and controls (N = 52) (categorized by p = 90%) Figure 1
Homocysteine concentration in patients (N = 51) and controls (N = 52) (categorized by p = 90%).
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et al [29] studied children with SLE and observed that
despite corticosteroid use, increase of Hcy concentration
was associated to disease activity. We did not observe
higher levels of TC in our JIA patients when compared to
controls. With regard to the HDL cholesterol fraction, our
patients showed decreased serum levels. This finding was
also observed by Urban et al [30] in their studies involving
patients with JIA.
Conclusion
JIA patients do not present significant increased concen-
tration of Hcy despite the use of MTX, probably due to the
folate supplementation. The mild abnormalities in the
lipidogram may reflect a current concern with diet and
health.
Our data is not conclusive. Multicentric studies involving
a higher number of patients will help to indicate with
more accuracy the significance of Hcy in patients with JIA.
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